Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 290 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... July 27, 2023 FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer January 4, 2021 Dr Ian Walker on Smoking: ‘The killer behind the counter’ March 17, 2023 Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... March 7, 2024 Load more HOT NEWS Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or...
